Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 18, 2016. The document serves as a transaction notification regarding a specific share acquisition by a Person Discharging Managerial Responsibilities (PDMR) rather than a comprehensive financial report.
Key Financial Metrics
The filing does not provide consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics for the company. It contains only transaction-specific data:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: £16.6781 per share.
- Transaction Volume: 32.477 shares.
- Transaction Date: July 14, 2016.
- Exchange: London Stock Exchange (XLON).
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a single acquisition event by Ms. C Thomas, SVP of HR, involving the re-investment of dividends paid on July 14, 2016, under the Deferred Annual Bonus Plan Post-Tax.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, future guidance, outlook, risk factors, contingencies, or unusual items. It is strictly a regulatory disclosure of an insider transaction.
Investor Verification Points
- Verify the total number of shares held by Ms. C Thomas post-transaction to assess insider ownership concentration.
- Confirm the dividend reinvestment terms of the Deferred Annual Bonus Plan Post-Tax.
- Check the market price of GSK ordinary shares on July 14, 2016, to validate the transaction price of £16.6781.